The stock of Entera Bio Ltd (NASDAQ: ENTX) has increased by 13.10% when compared to last closing price of $1.45.Despite this, the company has seen a gain of 36.67% in its stock price over the last five trading days.
Is It Worth Investing in Entera Bio Ltd (NASDAQ: ENTX) Right Now?
The 36-month beta value for ENTX is at 1.83. Analysts have varying views on the stock, with 1 analysts rating it as a “buy”, 0 rating it as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for ENTX is 34.54M, and currently, shorts hold a 0.30% of that float. The average trading volume for ENTX on February 12, 2026 was 183.77K shares.
ENTX’s Market Performance
ENTX’s stock has seen a 36.67% increase for the week, with a 4.46% rise in the past month and a -45.33% fall in the past quarter. The volatility ratio for the week is 18.56%, and the volatility levels for the past 30 days are at 12.00% for Entera Bio Ltd The simple moving average for the past 20 days is 13.38% for ENTX’s stock, with a -18.92% simple moving average for the past 200 days.
Analysts’ Opinion of ENTX
Many brokerage firms have already submitted their reports for ENTX stocks, with Aegis Capital repeating the rating for ENTX by listing it as a “Buy”. The predicted price for ENTX in the upcoming period, according to Aegis Capital is $12 based on the research report published on March 22, 2021 of the previous year 2021.
ENTX Trading at -4.88% from the 50-Day Moving Average
After a stumble in the market that brought ENTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.07% of loss for the given period.
Volatility was left at 12.00%, however, over the last 30 days, the volatility rate increased by 18.56%.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ENTX starting from Rubin Steven D, who purchase 10,000 shares at the price of $1.20 back on Feb 09 ’26. After this action, Rubin Steven D now owns 10,000 shares of Entera Bio Ltd, valued at $12,000 using the latest closing price.
Ellis Sean, the Director of Entera Bio Ltd, purchase 18,000 shares at $1.24 during a trade that took place back on Feb 09 ’26, which means that Ellis Sean is holding 178,098 shares at $22,320 based on the most recent closing price.
Stock Fundamentals for ENTX
Current profitability levels for the company are sitting at:
- -87.29% for the present operating margin
- -0.06% for the gross margin
The net margin for Entera Bio Ltd stands at -86.94%. The total capital return value is set at -0.68%. Equity return is now at value -99.43%, with -85.74% for asset returns.
Based on Entera Bio Ltd (ENTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -34.39. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1546.29.
Currently, EBITDA for the company is -$9.54 million with net debt to EBITDA at 0.78. When we switch over and look at the enterprise to sales, we see a ratio of 539.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.83.
Conclusion
In conclusion, Entera Bio Ltd (ENTX) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.